AZN — AstraZeneca Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24,384	26,617	37,417	44,351	45,811
Cost of Revenue
Gross Profit	19,560	21,347	27,875	35,702	37,743
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	21,460	21,455	36,361	40,594	37,618
Operating Profit	2,924	5,162	1,056	3,757	8,193
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,548	3,916	-265	2,501	6,899
Provision for Income Taxes
Net Income After Taxes	1,227	3,144	115	3,293	5,961
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,335	3,196	112	3,288	5,955
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	1,335	3,196	112	3,288	5,955
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.49	1.89	2.77	3.53	3.41
Dividends per Share